BioSpace.com

Biotech and Pharmaceutical
News & Jobs
Search the Site
 
   
Biotechnology and Pharmaceutical Channel Medical Device and Diagnostics Channel Clinical Research Channel BioSpace Collaborative    Job Seekers:  Register | Login          Employers:  Register | Login  

NEWSLETTERS
Free Newsletters
Archive
My Subscriptions

NEWS
News by Subject
News by Disease
News by Date
PLoS
Search News
Post Your News
JoVE

CAREER NETWORK
Job Seeker Login
Most Recent Jobs
Browse Biotech Jobs
Search Jobs
Post Resume
Career Fairs
Career Resources
For Employers

HOTBEDS
Regional News
US & Canada
  Biotech Bay
  Biotech Beach
  Genetown
  Pharm Country
  BioCapital
  BioMidwest
  Bio NC
  BioForest
  Southern Pharm
  BioCanada East
  US Device
Europe
Asia

DIVERSITY

INVESTOR
Market Summary
News
IPOs

PROFILES
Company Profiles

START UPS
Companies
Events

INTELLIGENCE
Research Store

INDUSTRY EVENTS
Biotech Events
Post an Event
RESOURCES
Real Estate
Business Opportunities

 News | News By Subject | News by Disease News By Date | Search News
eNewsletter Signup
Miles
Km80.5

   

Emerging World Pharma Inc. Strategic Partner African Global Pharma (AGP) Approval From Food & Drugs Board Ghana for Anti-Malarial Pharmaceutical Gloderp® in Final Stages


11/28/2012 9:23:57 AM

SUNYANI, GHANA--(Marketwire - November 28, 2012) -

Emerging World Pharma Inc. (PINKSHEETS: EWPI) strategic partner African Global Pharma Corp. (AGP) has informed us that the Food and Drugs Board of Ghana approval of the anti-malarial pharmaceutical Gloderp® is in the final stages of the registration process with the company anticipating full approval before this quarter end. The Food and Drugs Board of Ghana is a Ghanaian government agency responsible for the inspection, certification and proper distribution of foods and food products and drugs in Ghana. There remains an ongoing demand for anti-malarial medicines in Ghana and surrounding African countries that is readily made available at affordable prices.

Upon approval African Global Pharma GH would be the only manufacturer of Golderp® in capsule form in Ghana. This would allow AGP to readily manufacture and distribute the anti-malarial medicine in an affordable and timely manner throughout Ghana and other West African countries. It will be produced in (AGP) Sunyani, Ghana manufacturing facility.

Gloderp® is used for the treatment of uncomplicated malaria caused by falciparum, vivax and or malariae. Each capsule will contain Dihydroartemisinin 40mg and Piperaquine Phosphate 320mg.

About African Global Pharma, Ghana
African Global Pharma (Ghana) Limited is an affiliated company of African Global Pharma Corp. of Canada with business partnership with the Catholic Diocese of Sunyani to distribute all our manufactured drugs to the Catholic Mission Hospitals. African Global Pharma's production facility in Sunyani, Ghana was fully rehabilitated and built by African Global Pharma Corp, Canada. The plant and its operations are headquartered in Sunyani at the Diocesan Bldg.

For more on AGP click here http://www.globalpharmacorp.ca/african-gp-ghana.html

About Emerging World Pharma Inc.
Emerging World Pharma Inc. is an investor in generic based pharmaceutical companies manufacturing within developing nations.

The company focuses its investments on generic pharmaceutical companies that have contracts with three major buyer groups; church, government and wholesalers. Market research shows that these branches are the most secure, protected and reputable for the distribution of medicines.

For more on Emerging World Pharma Inc. click here http://www.emergingpharma.com/

Forward Looking Statements

This press release contains "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995. Statements in this release that are forward-looking statements are based on current expectations and assumptions that are subject to known and unknown risks, uncertainties, or other factors which may cause actual results, performance, or achievements of the company to be materially different from any future results, performance, or achievements expressed or implied by such forward-looking statements. Actual results could differ materially because of factors such as the effect of general economic and market conditions, entry into markets with vigorous competition, market acceptance of new products and services, continued acceptance of existing products and services, technological shifts, and delays in product development and related product release schedules, any of which may cause revenues and income to fall short of anticipated levels. All information in this release is as of the date of this release. The company undertakes no duty to update any forward-looking statement to conform the statement to actual results or changes in the company's expectations.


Contact:
Joel Everret
Emerging World Pharma Inc.
Investor Relations Division
703-646-2633
Email: info@emergingpharma.com
Website: http://www.emergingpharma.com/



Read at BioSpace.com

   
Malaria

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES